Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension

L. Narine, L. K. Hague, J. H. Walker, C. Vicente, R. Schilz, O. Desjardins, T. R. Einarson, M. Iskedjian

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Fingerprint

Dive into the research topics of 'Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension'. Together they form a unique fingerprint.

Medicine & Life Sciences